Most people with COVID-19 recover at home with rest, fluids, and basic over-the-counter medications. For those at higher risk of severe illness, prescription antiviral treatments can significantly reduce the chance of hospitalization, but they need to be started within five days of your first symptoms. What you do and how quickly you act depends on your symptoms and your personal risk factors.
Managing Mild Symptoms at Home
The majority of COVID infections cause mild to moderate illness. Fever, body aches, sore throat, congestion, cough, and fatigue are the most common symptoms, and they typically resolve on their own within one to two weeks. Over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen (Advil, Motrin) can help bring down fever and ease aches. Standard cold remedies, including cough suppressants, throat lozenges, and decongestants, work the same way they would for any respiratory virus.
Staying hydrated matters more than people realize. Fever, sweating, and reduced appetite can quietly dehydrate you, which makes fatigue and headaches worse. Water, broth, and electrolyte drinks are all good choices. Rest as much as your body asks for, even if you start feeling better partway through. Pushing too hard too early can drag out recovery.
Monitoring Your Oxygen at Home
A pulse oximeter, the small clip-on device that reads your blood oxygen through your fingertip, is one of the most useful tools for tracking COVID at home. Before taking a reading, rest for at least five minutes and warm your hands. Remove nail polish or fake nails, place your middle or index finger in the device, and hold still for about a minute until the number stabilizes for at least five seconds. Record the highest steady reading.
An oxygen saturation (SpO2) above 94% is normal. Continue checking three times a day. If your level falls between 90% and 94%, contact your doctor or head to a clinic. If it drops below 90%, get immediate medical help. Regardless of what the number says, seek emergency care if you experience trouble breathing, persistent chest pain or pressure, new confusion, inability to stay awake, or bluish lips or face.
Who Qualifies for Prescription Antivirals
Antiviral medications are reserved for people at higher risk of ending up in the hospital. You’re generally eligible for treatment if you’re 50 or older, or if you have a condition that increases your risk of severe COVID. The list of qualifying conditions is broad:
- Chronic diseases: diabetes (type 1 or 2), chronic kidney disease at any stage, chronic liver disease, heart conditions including heart failure and coronary artery disease, and chronic lung diseases like COPD and moderate-to-severe asthma
- Immune system factors: cancer (especially if on chemotherapy), organ or stem cell transplant, HIV, long-term use of immunosuppressive medications, or primary immunodeficiency
- Other risk factors: obesity (BMI of 30 or higher), pregnancy, smoking (current or former), cerebrovascular disease, dementia or other neurological conditions, and certain disabilities
- Mental health and substance use: mood disorders including depression, schizophrenia spectrum disorders, and substance use disorders
Being unvaccinated or behind on COVID boosters also raises your risk substantially. The more risk factors you have, the more important early treatment becomes.
Paxlovid: The First-Line Treatment
Paxlovid (nirmatrelvir with ritonavir) is the most commonly prescribed outpatient antiviral for COVID-19. It’s a five-day course of pills taken twice daily, and it needs to be started as soon as possible, within five days of your first symptoms. The earlier you begin, the more effective it is at preventing progression to severe illness.
Paxlovid works by blocking an enzyme the virus needs to replicate, essentially slowing the infection enough for your immune system to catch up. The main complication is drug interactions. Paxlovid affects how your liver processes many common medications, including certain blood thinners, cholesterol drugs, and heart medications. Your doctor or pharmacist will review your medication list before prescribing it. People with severe kidney or liver problems may not be able to take it, and dosing adjustments are sometimes needed for those with reduced kidney function. No special lab tests are required before starting.
If you test positive and have risk factors, call your doctor promptly. The five-day window closes fast, and getting a prescription on day four or five is far less ideal than starting on day one or two.
When Paxlovid Isn’t an Option
For people who can’t take Paxlovid because of drug interactions or other medical reasons, two alternatives exist. Remdesivir (Veklury) is an approved antiviral that requires three days of intravenous infusions, which makes it less convenient but still effective for outpatients who can access an infusion center.
Molnupiravir (Lagevrio) is an oral antiviral authorized specifically for situations where neither Paxlovid nor remdesivir is accessible or appropriate. It’s less potent: in clinical trials, it reduced the risk of hospitalization or death by about 30% compared to placebo, with 7.3% of treated patients hospitalized versus 14.1% on placebo. Paxlovid has shown stronger efficacy in comparison, which is why molnupiravir is positioned as a backup rather than a first choice.
Treatment for Hospitalized Patients
When COVID progresses to the point where someone needs hospital care, typically when oxygen levels drop to 94% or below, the treatment approach shifts. Remdesivir is the primary antiviral used in hospital settings, given intravenously for five days. It works by interfering with the virus’s ability to copy its genetic material, slowing viral replication.
Corticosteroids, particularly dexamethasone, play a central role for patients who need supplemental oxygen. Severe COVID can trigger an overactive immune response that damages the lungs and other organs, and steroids help dial that inflammation down. This treatment is typically continued for up to 10 days or until discharge. For critically ill patients on mechanical ventilation, dexamethasone is strongly recommended based on evidence showing reduced mortality.
Tocilizumab (Actemra) is another option for hospitalized adults with severe illness. It targets a specific part of the inflammatory cascade and is approved as an add-on treatment when the immune system’s overreaction is driving the damage.
What Happened to Monoclonal Antibodies
If you remember monoclonal antibody infusions being a major part of COVID treatment in 2021 and 2022, the landscape has changed dramatically. The FDA revoked authorization for nearly all of those earlier products, including bamlanivimab/etesevimab, bebtelovimab, REGEN-COV (casirivimab/imdevimab), sotrovimab, and Evusheld. The reason is straightforward: the virus mutated, and these antibodies no longer effectively neutralize current circulating variants.
One newer product, pemivibart (Pemgarda), received emergency authorization in March 2024 for prevention in immunocompromised individuals. But for most people seeking treatment after infection, oral antivirals have replaced monoclonal antibodies as the standard approach.
The Timing That Matters Most
The single most important factor in COVID treatment, beyond rest and fluids, is speed. Antivirals work by slowing viral replication during the window when the virus is still multiplying rapidly. Once the illness progresses to the point where your immune system’s inflammatory response is causing the damage rather than the virus itself, antivirals become far less useful.
If you test positive and you’re over 50 or have any of the risk factors listed above, contact your healthcare provider the same day. Have a plan in place before you get sick: know how to reach your doctor on weekends, whether your pharmacy stocks Paxlovid, and whether a telehealth visit is an option for getting a prescription quickly. Many people who qualify for treatment never receive it simply because they waited too long or didn’t realize they were eligible.